MONOMERIC CALCITONIN (CT) DEFICIENCY I N PATIENTS WITH CONGENITAL NON GOITROUS HYPOTHYROIDISM (CH) DURING EARLY INFANCY. CT d e f i c i e n c y h a s been r e p o r t e d i n c h i l d r e n and a d o l e s c e n t s w i t h Cll;bbt whether i t i s a l s o d e f i c i e n t i n CH p a t i e n t s d u r i n g infancy h a s n o t been i n v e s t i g a t e d . Plasma e x t r a c t i o n of CT has much improved t h e s e n s i t i v i t y and s p e c i f i c i t y of CT radioimmunoassays f o r t h e measurement of t h e monomeric CT form, t h e a c t i v e form of t h i s hypocalcemic hormone. To f u r t h e r analyze
CT s e c r e t i o n i n e a r l y infancy, we measured CT and Calcium (Cn) v a l u e s i n I) normal i n f a n t s aged 0-2 y r s ( g r . NL-I, n=39) and 2-5 y r s ( g r . NL-2, n=12) and 2) CH i n f a n t s aged 0-2 y r s ( g r . CH-I, n=6) and 2-5 y r s ( g r . CH-2,114) R e s u l t s a r e shown i n t h e t a b l e (Mean !: SEM):( XX pC0,OI a s compar e d t o groups NL) gr.NL-l gr.CH-l I gr.NL-2 g r . CH-2 CT(pglm1) 12.86+1.12 3 . 2 3 t 0 . 6 3~~ 6.48+1 . I 6 1 . 2 5 + 0 . 0 6~~ Ca(mgId1) 9.73+0.09 9.73t0.20 9.65+0.08 9.57+0.11 The d a t a show t h a t CT values I) d e c r e a s e d u r i n g t h e f i r s t y e a r s of l i f c i n b o t h normal and CH p a t i e n t s , and 2) a r e lower i n CH than i n normal s u b j e c t s . I n conclusion: I) low b u t d e t e c t a b l e v a l u e s of CT a r e p r e s e n t i n CH p a t i e n t s , i n d i c a t i n g t h a t f u n c t i o n a l c a l c i t on i n s e c r e t i n g c e l l s do e x i s t i n t h e s e p a t i e n t s ; 2) t h e low CT l e v e l s i n i n f a n t s w i t h CH a s compared w i t h normal s u b j e c t s suggest t h a t CT d e f i c i e n c y could have an important pathogenic r o l e i n t h e hypercalcemia o c c a s i o n a l l y observed i n CH p a t i e n t s d u r i n g t h e n e o n a t a l period. were tested for their capacity to distinguish patients from euthyroid infante. The various meth involved assessment of the shape and size of ossifi tion centers in the knee and ankle regions. All f methods revealed statistically significant retar J Le er*, C.Tau*, M.Garabedian*, P.Czernichow e t r i c Endocrinology and Diabetes
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Yrpercalcemia has been described in infants with M before and after treatment with lhyroxine (T4). In a group of 25 infants, hypercalcemia during T4 therapy was related to vit D supplementation (in France 1200iuld). To study further adequate vit D dosage to maintain normal Ca levels, 2 groups of infants were studied during the first 6 months of life. Group I (11x5) without and Group I1 (n=10) with 400 iu/d of vit D. Senm Ca (mg/dl +SEM) and 250HD were measured at diagnosis (<lmonth) before treatment, and at 2, 4 and 6 months of life. .llp(0.hgmpI In group I, Ca was normal and 25(OH)D was: 15+5, 7+4, 9+2 nglml at 2, 4 and 6 months. In 1 case however, hypocalcemia and low 25(OH)D occured at 3 months of age and necesssitated vit D administration. In group 11. Ca was moderately elevated with a significant difference between the 2 groups at 4 months. 25(OH)D levels were 17+2, 21+6, 15+2 ng/ml at 2, 4, 6 months, within the normal range in France. In conclusion: in infants with (31, low dosage of Vit D is associated with hypercalcemia whereas infants receiving no vit D are at risk of hypocalcemia. Vit D supplementation should be given with caution to infants with CH up to the 6th month of age and carefully controlled by s e m Ca measurement.
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THYROXIN (T4) EFFECTS ON GROWTH AND HEPATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGF) ONTOGENY IN MICE WITH CONGENITAL HYPO-THYROIDISM (CH).
The effects of thyroid hormones on growth and development are probably mediated by specific growth factors as EGF. We have studied the effects of thyroxine on growth and hepatic EGF receptor ontogeny in a mouse strain with an inherited form of CH. Hypothyroid mice (h/h) were treated with T4 between day 20 and day 40 postnatally, h/h nontreated mice and euthyroid (+I+) mice served as controls. Animals were killed at day 20 or day 40 postnatally. Serum thyroxine was measured by RIA and EGF receptor binding in a liver plasma-membrane homogenate. Up to 20 days of age all mice showed the same weight gain and EGF hepatic receptor binding were low and not significantly different between h/h and +/+ mice. From day 20 h/h mice had a significantly lower growth rate than +/+ mice, a growth retardation that were normalised by T4 To e x p l o r e t h i s , we s t u d i e d t h e h a l f -l i f e of a-FP d u r i n g t h e f i r s t month of l i f e i n neonates with CH and neonates w i t h t r a n s i e n t hyperthyrotropinaemia (TH), which we considered a s t h e c o n t r o l group. Between t h e 3 r d and 7 t h day of l i f e a-FP was measured i n 60 c a s e s with CH with a mean g e s t at i o n o l age of 39.W-1.5 weeks ard i n 184 c a s e s with Ttl with a mean g e s t a t i o n a l age of 3 9 . 3~1 . 9 weeks. The mean l o g a-FP l e v e l s i n t h e two groups were 4.35+0.39ng/ml and 3.97+0.36ng/ml r e s p e c t i v el y (p <0.01). Levels of ~X P were a l s o measured i n 6 1 c a s e s with CH a t a mean age of 29.8i12.9 d a y s and i n 37 c a s e s with TH a t a mean a g e of 36.5t13.1 d a y s . The r e s p e c t i v e mean v a l u e s of l o g a-FP were 3.84+0.46ng/ml and 2.71+0.55ng/ml,after adjustment f o r c o n c e p t i o n a l a g e d i f f e r e n c e s ( p < 6,001). The half -l i f e o f a-FP was 15.7 d a y s f o r t h e CH group and 7.7 d a y s f o r t h e TH group. The h a l f -l i f e of a-FP was a l s o c a l c u l a t e d i n each of 39 c a s e s with Ch and 8 c a s e s w i t h TH f o r which t h e r e were s e r i a l measurements of a-FP. The h a l f -l i f e of a-FP i n t h e two groups was 1 2 d a y s and 4.9 d a y s , r e s p e c t i v e l y . W e conclude t h a t catabolism of a-FP is delayed i n CH group, r e s u l t i n g i n inceased serum l e v e l s of a-FP. The l a c k of t h y r o i d hormones, and e s p e c i a l l y of T3, is probably r e s p o n s i b l e f o r t h a t . In phase I Tg was detectable in 8/16 patients which indicates that some thyroid secretion occurs in treated patients. Tg levels increase in phase I1 (range 6 to 50 nglml) which demonstrates in all cases the presence of actively secreting renmant tissue responsive to TSH stimulation. The low levels of FT4 and FT3 may indicate some thyroid hormone production in patients off therapy for one month. In conclusion: Ectopic thyroid doesn't involuate during the 5 first years of life. Tg measurement is an efficient tool to evaluate remnant thyroid tissue if the patient are investigated under appropriate TSH stimulation.
